Differential gene expression in the kidney of sickle cell transgenic mice: Upregulated genes

Blood Cells, Molecules, and Diseases

Volumn 31, Issue 3, 2003, Pages 370-380

  Rybicki, Anne C ^a   Fabry, Mary E ^a   Does, Mark D ^a   Kaul, Dhananjay K ^a   Nagel, Ronald L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALKALINE PHOSPHATASE; ARGINASE; CYTOCHROME P450 4A14; GLUTATHIONE TRANSFERASE ALPHA 1; HYDROXY ACID OXIDASE A; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; ISOENZYME; RENIN; RETINOL DEHYDROGENASE; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HYPOXIA; KIDNEY DISEASE; MITOCHONDRION; NONHUMAN; NUCLEOTIDE SEQUENCE; OXYGEN BLOOD LEVEL; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TRANSGENIC MOUSE; UPREGULATION;

MUS MUSCULUS;

EID: 0242468086     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2003.08.002     Document Type: Article

References (85)

1. Nagel R.L. Sickle cell anemia is a multigene disease sickle painful crisis, a case in point. Am. J. Hematol. 42:1993;96-101. (Review).
2. Embury S.H., Clark M.R., Monroy G., et al. Concurrent sickle cell anemia and α-thalassemia effect on pathological properties of sickle erythrocytes. J. Clin. Invest. 73:1984;116-123.
3. S gene. Fleming A.F. Bailliere's Clinical Haematology. 1992;331 Harcourt Brace Jovanovich, London, England.
4. Miyoshi K., Kaneto Y., Kawai H., et al. X-linked dominant control of F-cells in normal adult life characterization of the Swiss type as hereditary persistence of fetal hemoglobin regulated dominantly by gene(s) on the X chromosome. Blood. 72:1988;1854-1860.
5. Dover G.J., Smith K.D., Chang Y.C., et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked factor many issues and some answers. von Hahn H.P. Experientia. Vol. 49:1993;15 Birkhauser Verlag, Basel, Switzerland.
6. Ataga K.I., Orringer E.P. Renal abnormalities in sickle cell disease. Am. J. Hematol. 63:2000;205-211.
7. Walker T.M., Beardsall K., Thomas P.W., Serjeant G.R. Renal length in sickle cell disease observations from a cohort study. Clin. Nephrol. 46:1996;384-398.
8. Keitel H.G., Thompson D., Itano H.A. Hyposthenuria in sickle cell anemia a reversible renal defect. J. Clin. Invest. 35:1956;998-1007.
9. Gupta A.K., Kirchner K.A., Nicholson R., Adams J.G. III, Schechter A.N., Noguchi C.T., Steinberg M.H. Effects of α-thalassemia and sickle polymerization tendency on the urine concentrating defect of individuals with sickle cell trait. J. Clin. Invest. 88:1991;1963-1968.
10. Strauss J., Zilleruelo G., Abitbol C. The kidney and hemoglobin S. Nephron. 43:1986;241-245.
11. Sabatini S. Pathophysiological mechanisms of abnormal collecting ducts. Semin. Nephrol. 9:1989;179-202.
12. Scheinman J.L. Sickle nephropathy. Barral T.M., Avner E.D., Armon W.E. Pediatric Nephrology. 4th Ed: 1999;497-507 Lippincott, Williams and Wilkins, Baltimore, MD.
13. Allon M. Renal abnormalities in sickle cell disease. Arch. Intern. Med. 150:1990;501-504.
14. Allon M., Lawson L., Eckman J.R., Delaney V., Bourke E. Effects of nonsteroidal anti-inflammatory drugs on renal function in sickle cell anemia. Kidney Int. 34:1988;500-506.
15. Smith E.C., Valika K.S., Mou J.E., O'Donnell J.G., Gordon D.L., Westerman M.D. Serum phosphate abnormalities in sickle cell anemia. Proc. Soc. Exp. Biol. Med. 168:1981;254-258.
16. Yassie D., Dasgupta A., Okolo A., Glew R.H. Lysosomal enzymuria in protein energy malnutrition. Am. J. Nephrol. 18:1998;9-15.
17. Branten A.J., Mulder T.P., Peters W.H., Assmann K.J., Wetzels J.F. Urinary excretion of glutathione-S-transferases alpha and pi in patients with proteinuria reflection of the site of tubular injury. Nephron. 85:2000;120-126.
18. Vogler C., Wood E., Lane P., Ellis E., Cole B., Thorpe C. Microangiopathic glomerupathy in children with sickle cell anemia. Ped. Pathol. Lab. Med. 16:1996;275-284.
19. Guasch A., Zagas C.F., Eckman J.R., Murfalidharan K., Zhang W., Elsas L.J. Evidence that microdeletions of the globin gene protect against development of sickle cell glomeropathy in humans. J. Am. Soc. Nephrol. 10:1999;1014-1101.
20. Smitt F., Martinez F., Brillet G., Giatras I., Choukroun G., Girt R., Bachir D., Galacteros F., Lacour B., Gruenfeld J.P. Early glomerular dysfunction in patients with sickle cell anemia. Am. J. Kidney Diseases. 32:1998;208-214.
21. Bakir A.A., Hathiwala S.C., Ainis H., Hryhorczuk D.O., Rhee H.L., Levy P.S., Dunea G. Prognosis of the nephrotic syndrome in sickle glomerulopathy. Am. J. Nephrol. 7:1987;110-115.
22. Pardo V., Strauss J., Klamer H., Ozawa T., McIntosh R.M. Nephropathy associated with sickle cell anemia an autologous immune complex nephritis II. Clinicopathologic study of seven patients. Am. J. Med. 59:1975;650-659.
23. Yoshida Y., Fogo A., Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int. 35:1989;654-660.
24. Nagel R.L., Fabry M.E. The panoply of animal models for sickle cell anemia. Br. J. Haematol. 112:2001;19-25.
25. Bank N., Aynedijan H.S., Qiu J., Fabry M.E., Nagel R.L. Renal nitric oxide synthases in transgenic sickle cell mice. Kidney Int. 50:1996;184-189.
26. Nath K.A., Grande J.P., Haggard J.J., Croatt A.J., Katusic Z.S., Solovey A., Hebbel R.P. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am. J. Pathol. 158:2001;893-903.
27. De Franceschi L., Baron A., Scarpa A., Adrie C., Janin A., Barbi S., Kister S., Rouyer-Fessard P., Corrocher R., Leboulch P., Beuzard Y. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood. 102:2003;1087-1096.
28. Fabry M.E., Sengupta A., Suzuka S.M., Costantini F., Rubin E.M., Hofrichter J., Christoph G., Manci E., Culberson D., Factor S.M., Nagel R.L. A second-generation transgenic mouse model expressing both Hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity. Blood. 86:1995;2419-2428.
29. Kaul D.K., Fabry M.E., Constantini F., Rubin E.M., Nagel R.L. In vivo demonstration of red cell endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J. Clin. Invest. 96:1995;2845-2853.
30. Kaul D.K., Liu X.D., Fabry M.E., Nagel R.L. Impaired nitric oxide mediated vasodilation in the transgenic sickle mouse. Am. J. Physiol. 278:2000;H1799-1806.
31. S- and α-globins in transgenic mice erythrocyte abnormalities, organ damage, and effect of hypoxia. Proc. Natl. Acad. Sci. USA. 89:1992;12155-12159.
32. Rubin E.M., Witkowska H.E., Spangler E., Curtin P., Lubin B.H., Mohandas N., Clift S.M. Hypoxia-induced in vivo sickling of transgenic mouse red cells. J. Clin. Invest. 87:1991;639-647.
33. Skow L.C., Burkhart B.A., Johnson F.M., Popp R.A., Popp D.M., Goldberg S.Z., Anderson W.F., Barnett L.B., Lewis S.E. A mouse model for beta-thalassemia. Cell. 34:1983;1043-1052.
34. Cheung V.G., Morley M., Aguilar F., Massimi A., Kucherlapati R., Childs G. Making and reading microarrays. Nat. Genet. 21:1999;15-19.
35. Mariadason J.M., Corner G.A., Augenlicht L.H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids. Cancer Res. 60:2000;4561-4572.
36. Morrison T.B., Weiss J.J., Wittwer C.T. Quantitation of low-copy transcripts by continuous SYBR green I monitoring during amplification. Biotechniques. 24:1998;954-958. 960, 962.
37. Callow M.J., Dudoit S., Gong E.L., Speed T.P., Rubin E.M. Microarray expression profiling identifies genes with altered expression in HDL-deficient mice. Genome Res. 10:2000;2022-2029.
38. Fabry M.E., Kennan R.P., Paszty C., Costantini F., Rubin E.M., Gore J.C., Nagel R.L. Magnetic resonance evidence of hypoxia in a homozygous α-knockout of a transgenic mouse model for sickle cell disease. J. Clin. Invest. 98:1996;2450-2455.
39. Romero J., Suzuka S.M., Nagel R.L., Fabry M.E. Arginine supplementation in sickle transgenic mice reduces red cell density and Gardos channel activity. Blood. 99:2002;1102-1108.
40. Escalante B., Omata K., Sessa W., Lee S.G., Falck J.R., Schwartzman M.L. 20-Hydroxyeicosatetraenoic acid is an endothelium-dependent vasoconstrictor in rabbit arteries. Eur. J. Pharmacol. 235:1993;1-7.
41. Ornata K., Abe K., Sheu H.L., Yoshida K., Tsutsumi E., Yoshinaga K., Abraham N.G., Laniado-Schwartzman M. Roles of renal cytochrome P450-dependent arachidonic acid metabolites in hypertension. Tohoku J. Exp. Med. 166:1992;93-106.
42. Escalante B., Erlij D., Falck J.R., McGiff J.C. Cytochrome P450-dependent arachidonate metabolites affect renal transport in the rabbit. J. Cardiovasc. Pharmacol. 22:(Suppl2):1993;S106-S108.
43. Imig J.D. Epoxygenase metabolites epithelial and vascular actions. Mol. Biotechnol. 16:2000;233-251.
44. Zhao X., Inscho E.W., Bondle M., Falck J.R., Imig J.D. The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction. Am. J. Physiol. Heart. Circ. Physiol. 281:2001;H2089-H2096.
45. Bank N., Kiroycheva M., Singhal P.C., Anthony G.M., Southan G.J., Szabo C. Inhibition of nitric oxide synthase ameliorates cellular injury in sickle cell mouse kidneys. Kidney Int. 58:2000;82-89.
46. Garvin J.L., Hong N.J. Nitric oxide inhibits sodium/hydrogen exchange activity in the thick ascending limb. Am. J. Physiol. 277:1999;F377-F382.
47. Ortiz P.A., Hong N.J., Garvin J.L. NO decreases thick ascending limb chloride absorption by reducing Na-K-2Cl cotransporter activity. Am. J. Physiol. (Renal Physiol.). 281:2001;F819-F825.
48. +-ATPase activity on unilateral urethral obstruction interaction of endogenous nitric oxide and angiotensin II. Kidney Int. 58:2000;1641-1651.
49. Ortiz P.A., Garvin J.L. Role of nitric oxide in the regulation of nephron transport. Am. J. Physiol. (Renal Physiol.). 282:2002;F777-F784.
50. Oyekan A.O., Youseff T., Fulton D., Quilley J., McGiff J.C. Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J. Clin. Invest. 104:1999;1131-1137.
51. Strange R.C., Spiteri M.A., Ramachandran S., Fryer A.A. Glutathione-S-transferase family of enzymes. Mutat. Res. 482:2001;21-26. (Review).
52. Olivier L.M., Krisans S.K. Peroxisomal protein targeting and identification of peroxisomal targeting signals in cholesterol biosynthetic enzymes. Biochem. Biophys. Acta. 529:2000;89-102.
53. Zaar K. Structure and function of peroxisomes in the mammalian kidney. Eur. J. Cell Biol. 59:1992;233-254.
54. Dansen T.B., Wirtz K.W. The peroxisome in oxidative stress. IUBMB Life. 51:2001;223-230.
55. Haque S.J., Harbor P.C., Williams B.R. Identification of critical residues for suppressor of cytokine signaling-specific regulation of interleukin-4 signaling. J. Biol. Chem. 275:2000;26500-26506.
56. Eyckerman S., Verhee A., der Hayden J.V., Lemmens I., Ostade X.V., Vanderkerckhove J., Tavernier J. Design and application of a cytokine receptor based interaction trap. Nat. Cell Biol. 3:2001;1114-1119.
57. Kitching A.R., Holdsworth S.R., Tipping P.G. Crescentic glomerulonephritis-a manifestation of a nephritogenic Th1 response? Histol. Histopathol. 15:2000;993-1003.
58. Zhai Y., Higgins D., Napoli J.L. Coexpression of the mRNAs encoding retinol dehydrogenase isozymes and cellular retinol-binding protein. J. Cell Physiol. 173:1997;36-43.
59. Xu Q., Konta T., Kitamura M. Retinoic acid regulation of mesangial cell apoptosis. Exp. Nephrol. 10:2002;171-175. (Review).
60. Kitamura M., Ishikawa Y., Moreno-Manzano V., Xu Q., Konta T., Lucio-Cazana J., Furusu A., Nakayama K. Intervention by retinoic acid in oxidative stress-induced apoptosis. Nephrol. Dial. Transplant. 17:(Suppl 9):2002;84-87. (Review).
61. Wu G., Morris S.M. Jr. Arginine metabolism nitric oxide and beyond. Biochem. J. 336:1998;1-17.
62. Waddington S.N., Cattell V. Arginase in glomerulonephritis. Exp. Nephrol. 8:2000;128-134.
63. Waddington S.N., Tam F.W., Cook H.T., Cattell V. Arginase activity is modulated by IL-4 and HOArg in nephritic glomeruli and mesangial cells. Am. J. Physiol. 274:1998;F473-F480.
64. Ozaki M., Gotoh T., Nagasaki A., Miyanaka K., Takeya M., Fujiyama S., Tomita K., Mori M. Expression of arginase II and related enzymes in the rat small intestine and kidney. J. Biochem. (Tokyo). 125:1999;586-593.
65. Miyanaka K., Gotoh T., Nagasaki A., Takeya M., Ozaki M., Iwase K., Takiguchi M., Iyama K.I., Tomita K., Mor M. Immunohistochemical localization of arginase II and other enzymes of arginine metabolism in rat kidney and liver. Histochem. J. 30:1998;741-751.
66. Jones J.M., Morrell J.C., Gould S.J. Identification and characterization of HAOX1, HAOX2, and HAOX3, three human peroxisomal 2-hydroxy acid oxidases. J. Biol. Chem. 275:2000;12590-12595.
67. Tintillier M., Pochet J.M., Blackburn D., Delgrange E., Donckier J.E. Hyperoxaluria an underestimated cause of rapidly progressive renal failure. Acta Clin. Belg. 56:2001;360-363.
68. Rumsby G. Biochemical and genetic diagnosis of the primary hyperoxalurias a review. Mol. Urol. 4:2000;349-354.
69. Nissenson A.R., Port F.K. Outcome of end-stage renal disease in patients with rare causes of renal failure I. Inherited and metabolic disorders. Q. J. Med. 73:1989;1055-1062.
70. Grege R. Physiology of renal sodium transport. Am. J. Med. Sci. 319:2000;51-62. (Review).
71. Narasimhan C., George T., George J.T., Pulimood B.M. Hypertension in sickle cell disease. J. Assoc. Physicians India. 38:1990;435-436.
72. Mullins L.J., Payne C.M., Kotelevtseva N., Brooker G., Fleming S., Harris S., Mullins J.J. Mice lacking a functional Ren-1 (d) gene exhibit a complete lack of renal juxtaglomerular cell granulation and atypical macula densa morphology. J. Biol. Chem. 275:2000;40378-40384.
73. Clark A.F., Sharp M.G., Morley S.D., Fleming S., Peters J., Mullins J.J. Renin-1 is essential for normal renal juxtaglomerular cell granulation and macula densa morphology. J. Biol. Chem. 272:1997;18185-18190.
74. Harris R.C. Jr. Cyclooxygenase-2 inhibition and renal physiology. Am. J. Cardiol. 89:2002;D10-17.
75. Yudd M., Llach F. Current medical management of secondary hyperparathyroidism. Am. J. Med. Sci. 320:2000;100-106.
76. Edwards R.M., Chapple I.L. Hypophosphatesia dental aspects and mode of inheritance. J. Clin. Periodontol. 20:1993;615-622.
77. Kruh J., Defer N., Tichonicky L. Molecular and cellular action of butyrate. C. R. Sci. Soc. Biol. Fil. 186:1992;12-25.
78. Atweh G.F., Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin. Hematol. 38:2001;367-373. (Review).
79. Ikuta T., Atweh G., Boosalis V., White G.L., Da Fonseca S., Boosalis M., Faller D.V., Perrine S.P. Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis. Ann. NY Acad. Sci. 850:1998;87-99. (Review).
80. Edwards R.M. Disorders of phosphate metabolism in chronic renal disease. Curr. Opin. Pharmacol. 2:2002;171-176.
81. Enwonwu C.O., Xu X.X., Turner E. Nitrogen metabolism in sickle cell anemia free amino acid plasma and urine. Am. J. Med. Sci. 300:1990;366-371.
82. Fleming I. Cytochrome P450 and vascular homeostasis. Circ. Res. 89:2001;753-762.
83. Ito O., Ornata K., Ito S., Hoagland K.M., Roman R.J. Effects of converting enzyme inhibitors on P-450 metabolism of arachidonic acid. Am. J. Physiol. (Regul. Integr. Comp. Physiol.). 280:2001;R822-R830.
84. Falk R.J., Scheinman J., Phillips G., Orringer E., Johnson A., Jennette J.C. Prevalence and pathological features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N. Engl. J. Med. 326:1992;910-915.
85. Bank N., Kiroycheva M., Ahmed F., Anthony G.M., Fabry M.E., Nagel R.L., Singhal P.C. Peroxynitrate formation and apoptosis in transgenic sickle cell mouse kidneys. Kidney Int. 54:1998;1520-1528.